Početna › Akutna bifentipska leukemija
Kliničke studije za Akutna bifentipska leukemija koje traže sudionike u SAD-u
37 studija za Akutna bifentipska leukemija traži sudionike na lokacijama širom Sjedinjenih Američkih Država.
Gradovi s najviše studija
- Seattle, WA15 studija
- Houston, TX11 studija
- New York City, NY10 studija
- Atlanta, GA9 studija
- Durham, NC8 studija
- Memphis, TN7 studija
- Chicago, IL7 studija
- Charlotte, NC6 studija
- Aurora, CO6 studija
- Baldwin Park, CA6 studija
- Portland, OR6 studija
- Los Angeles, CA6 studija
- Philadelphia, PA6 studija
- Dallas, TX6 studija
- San Diego, CA5 studija
- San Francisco, CA5 studija
- Boston, MA5 studija
- Tampa, FL5 studija
- Clifton, NJ5 studija
- Columbus, OH5 studija
- Nashville, TN5 studija
- Greenburgh, NY5 studija
- Cincinnati, OH5 studija
- Fort Worth, TX5 studija
- Minneapolis, MN5 studija
- Mountain View, CA4 studija
- Jacksonville, FL4 studija
- Denver, CO4 studija
- Milwaukee, WI4 studija
- Greenville, NC4 studija
- St. Louis, MO4 studija
- Kansas City, MO4 studija
- Queens, NY4 studija
- Gainesville, FL4 studija
- Cleveland, OH4 studija
- Orange, CA4 studija
- Washington, DC4 studija
- Baltimore, MD4 studija
- Louisville, KY4 studija
- Miami, FL4 studija
Po državama
- Alabama3 studija
- Aljaska3 studija
- Arizona3 studija
- Arkansas3 studija
- Colorado8 studija
- Connecticut3 studija
- Delaware3 studija
- Distrikt Columbia4 studija
- Florida9 studija
- Georgia9 studija
- Havaji3 studija
- Idaho3 studija
- Illinois7 studija
- Indiana4 studija
- Iowa4 studija
- Kalifornija15 studija
- Kentucky4 studija
- Louisiana4 studija
- Maine3 studija
- Maryland4 studija
- Massachusetts5 studija
- Michigan4 studija
- Minnesota6 studija
- Mississippi3 studija
- Missouri5 studija
- Nebraska4 studija
- Nevada3 studija
- New Hampshire3 studija
- New Jersey6 studija
- New York11 studija
- North Carolina11 studija
- North Dakota3 studija
- Ohio8 studija
- Oklahoma5 studija
- Oregon6 studija
- Pennsylvania6 studija
- Rhode Island3 studija
- South Carolina3 studija
- South Dakota3 studija
- Tennessee10 studija
- Texas13 studija
- Utah3 studija
- Virginia3 studija
- Washington15 studija
- West Virginia3 studija
- Wisconsin5 studija
Nedavno ažurirane studije
Službeni tekst studije (engleski)
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
U tijeku regrutacijaFaza 1
Od 12 do 78 godina · Oba spola · Ažurirano 29. ruj 2026. · NCT03802695Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
U tijeku regrutacijaFaza 2
365 Days · Oba spola · Ažurirano 25. ruj 2026. · NCT06317662CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 17. ruj 2026. · NCT04375631Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid Neoplasms
U tijeku regrutacija
Od 18 godina i više · Oba spola · Ažurirano 17. ruj 2026. · NCT07094750A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
U tijeku regrutacijaFaza 1/2
30 Days · Oba spola · Ažurirano 16. ruj 2026. · NCT04065399Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 14. ruj 2026. · NCT03683433Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
U tijeku regrutacijaFaza 1/2Zdravi dobrovoljci dobrodošli
Do 50 godina · Oba spola · Ažurirano 1. ruj 2026. · NCT05322850Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
U tijeku regrutacijaFaza 3
365 Days – 25 Years · Oba spola · Ažurirano 25. kol 2026. · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
U tijeku regrutacijaFaza 1/2
Do 22 godina · Oba spola · Ažurirano 25. kol 2026. · NCT04726241Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
U tijeku regrutacijaFaza 2
Od 1 do 18 godina · Oba spola · Ažurirano 10. kol 2026. · NCT06390319Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
U tijeku regrutacijaFaza 1/2
Od 13 do 90 godina · Oba spola · Ažurirano 6. kol 2026. · NCT06533579Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
U tijeku regrutacijaFaza 1
Od 1 do 30 godina · Oba spola · Ažurirano 3. kol 2026. · NCT06177067Personalized NK Cell Therapy in CBT
U tijeku regrutacijaFaza 2
Od 15 do 80 godina · Oba spola · Ažurirano 30. srp 2026. · NCT02727803Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
U tijeku regrutacijaFaza 2
6 Months – 65 Years · Oba spola · Ažurirano 22. srp 2026. · NCT06013423Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 20. srp 2026. · NCT07046078Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
U tijeku regrutacijaFaza 4
Od 1 do 18 godina · Oba spola · Ažurirano 14. srp 2026. · NCT06289673Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 7. srp 2026. · NCT07216443Allo HSCT Using RIC and PTCy for Hematological Diseases
U tijeku regrutacijaFaza 2
Do 75 godina · Oba spola · Ažurirano 6. srp 2026. · NCT05805605Registry of Older Patients With Cancer
U tijeku regrutacijaOpažajna studija
Od 65 godina i više · Oba spola · Ažurirano 29. lip 2026. · NCT01137825Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT
U tijeku regrutacijaFaza 1
Od 18 do 70 godina · Oba spola · Ažurirano 23. lip 2026. · NCT06551584211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
U tijeku regrutacijaFaza 1/2
Od 18 do 75 godina · Oba spola · Ažurirano 22. lip 2026. · NCT03128034211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
U tijeku regrutacijaFaza 1/2
Od 18 do 75 godina · Oba spola · Ažurirano 22. lip 2026. · NCT03670966A Study of Revumenib and Mezigdomide in People With Leukemia
U tijeku regrutacijaFaza 1/2
Od 12 godina i više · Oba spola · Ažurirano 22. lip 2026. · NCT07356154Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 12. lip 2026. · NCT04047641Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
U tijeku regrutacijaFaza 2Zdravi dobrovoljci dobrodošli
6 Months · Oba spola · Ažurirano 29. svi 2026. · NCT04195633Iz ClinicalTrials.gov, podaci preuzeti 4. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.